胶质母细胞瘤扰动数据：放疗、药物与 CRISPR
虚拟细胞要学习状态对干预的反应，需要扰动数据。文献库中 GBM 相关的有：小鼠模型中结合放疗的体内 Perturb-seq、药物特征谱整合、类器官药物筛选，以及一项类器官替莫唑胺预印本；大规模扰动图谱大多非 GBM。
扰动
基因、药物与放射扰动数据——虚拟细胞所需的“干预→状态”配对数据。
关联证据
- VC0042 Tahoe-100M: Mapping drug-induced molecular phenotypes at single-cell resolution. — Zhang J et al., Cell, 2026
- VC0019 Predicting cellular responses to perturbation across diverse contexts with State. — Adduri AK et al., Cell, 2026
- VC0130 UniPert-G2CP bridges genetic and chemical screens from molecular representation to phenotype modeling — Li et al., Cell, 2026
- VC0097 Automated and personalized glioblastoma tumor organoid drug screening platform exposes sensitivity to proteasome and HDAC inhibitors. — Jungwirth G et al., NPJ precision oncology, 2026
- VC0132 Drug and single-cell gene expression integration identifies sensitive and resistant glioblastoma cell populations — Suter et al., Nature Communications, 2026
- VC0095 BRD2 bromodomain-mediated regulation of cell state plasticity modulates therapy response in glioblastoma. — Vadla R et al., Neuro-oncology, 2025
- VC0129 · 预印本 DELPHAI, AI Agent for Predicting Drug Response and Resistance — Peng et al., preprint, 2025
- VC0048 Deep-learning-based gene perturbation effect prediction does not yet outperform simple linear baselines. — Ahlmann-Eltze C, Huber W, Anders S., Nature methods, 2025
- VC0041 · 预印本 Tahoe-100M : A Giga-Scale Single-Cell Perturbation Atlas for Context-Dependent Gene Function and Cellular Modeling — Zhang J et al., bioRxiv, 2025
- VC0070 In vivo perturb-seq of cancer and microenvironment cells dissects oncologic drivers and radiotherapy responses in glioblastoma. — Liu SJ et al., Genome biology, 2024
- VC0040 Mapping information-rich genotype-phenotype landscapes with genome-scale Perturb-seq. — Replogle JM et al., Cell, 2022